- GSK’s adjusted earnings per share (EPS) surpassed estimates, reaching 46.5 pence compared to the expected 42.4 pence.
- Total revenue came in at GBP 7.99 billion, exceeding the estimated GBP 7.84 billion.
- Specialty Medicines sales hit GBP 3.33 billion, higher than the anticipated GBP 3.25 billion.
- Vaccines sales amounted to GBP 2.09 billion, beating the expected GBP 1.95 billion.
- General Medicines sales were slightly below expectations at GBP 2.57 billion versus an estimate of GBP 2.7 billion.
- Shingrix led the individual product highlights with revenue of GBP 853 million, above the forecasted GBP 795.6 million.
- Arexvy recorded sales of GBP 66 million, surpassing the estimate of GBP 61.4 million.
- Bexsero also outperformed estimates with revenue of GBP 282 million, compared to the GBP 242.2 million forecast.
- Trelegy Ellipta sales reached GBP 835 million, exceeding the expected GBP 821.2 million.
- Tivicay sales were GBP 333 million, above the estimated GBP 287.7 million.
- Dovato sales came in at GBP 655 million, beating the forecasted GBP 611.3 million.
- Cabenuva achieved revenue of GBP 341 million, surpassing the estimate of GBP 315.7 million.
- Benlysta sales amounted to GBP 451 million, above the expected GBP 437.3 million.
- Adjusted operating profit was GBP 2.63 billion, surpassing the estimated GBP 2.49 billion.
- The adjusted operating margin was 32.9%, better than the projected 31.9%.
- A dividend of 16 pence per share was declared.
- Research and Development (R&D) expenses were GBP 1.52 billion, slightly above the estimate of GBP 1.49 billion.
- General and administrative expenses were managed well, reaching GBP 2.09 billion, below the forecasted GBP 2.22 billion.
- GSK revised its full-year 2025 guidance at constant exchange rates (CER).
- In February 2025, GSK outlined improved outlooks for 2031.
- Current analyst ratings include 6 buys, 14 holds, and 5 sells.
“`
A look at GlaxoSmithKline PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
GlaxoSmithKline PLC, a research-based pharmaceutical company, is projected to have a promising long-term outlook based on the Smartkarma Smart Scores. With a strong focus on dividends and a decent showing in growth, resilience, and momentum, the company demonstrates a stable and reliable performance across various key factors. While the value score is not the highest, GlaxoSmithKline PLC‘s overall outlook appears to be positive, offering potential for investors seeking steady income and moderate growth in the pharmaceutical sector.
Operating in the development, manufacturing, and marketing of a wide range of healthcare products including vaccines, prescription drugs, and consumer health items, GlaxoSmithKline PLC caters to diverse health needs such as infections, depression, skin conditions, and chronic diseases. With a balanced combination of strong dividends and respectable growth, the company positions itself as a solid choice for investors looking for stability and consistent performance in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
